drugset / Trial / NCT00000801

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

NCT00000801 ↗

Treatment

Summary

To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.

Timeline

Start
—
Primary completion
—
Completion
1998-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — Intravenous
Subject Cytarabine Small molecule — Intrathecal
Subject Dexamethasone Small molecule — Intravenous
Subject Doxorubicin Other / unclassified — Intravenous
Subject Vincristine Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous